These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22120442)

  • 1. Preventive pharmacological treatment --an evolving new concept in schizophrenia.
    Sabbag R; Levin R; Edelman S; Heresco-Levy U
    Isr J Psychiatry Relat Sci; 2011; 48(2):82-90. PubMed ID: 22120442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early intervention and the treatment of prodrome in schizophrenia: a review of recent developments.
    Mokhtari M; Rajarethinam R
    J Psychiatr Pract; 2013 Sep; 19(5):375-85. PubMed ID: 24042243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early detection and intervention of schizophrenia: rationale and research.
    McGlashan TH
    Br J Psychiatry Suppl; 1998; 172(33):3-6. PubMed ID: 9764119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.
    Tcheremissine OV; Castro MA; Gardner DR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):7-14. PubMed ID: 22059602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New York high risk project to the Hillside recognition and prevention (RAP) program.
    Cornblatt BA
    Am J Med Genet; 2002 Dec; 114(8):956-66. PubMed ID: 12457393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevention of schizophrenia.
    Yung AR; Killackey E; Hetrick SE; Parker AG; Schultze-Lutter F; Klosterkoetter J; Purcell R; Mcgorry PD
    Int Rev Psychiatry; 2007 Dec; 19(6):633-46. PubMed ID: 18092241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prepsychotic treatment for schizophrenia: preventive medicine, social control, or drug marketing strategy?
    Gosden R
    Ethical Hum Sci Serv; 1999; 1(2):165-77. PubMed ID: 15586454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethics of the early intervention in the treatment of schizophrenia.
    Filaković P; Degmecić D; Koić E; Benić D
    Psychiatr Danub; 2007 Sep; 19(3):209-15. PubMed ID: 17914322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pre-psychotic states--contemporary diagnostic and therapeutic issues. Part I. Clinical identification of pre-psychotic states].
    Czernikiewicz A; Szulc A
    Psychiatr Pol; 2007; 41(1):5-15. PubMed ID: 17494410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The schizophrenia prodrome: treatment and high-risk perspectives.
    Cornblatt B; Lencz T; Obuchowski M
    Schizophr Res; 2002 Mar; 54(1-2):177-86. PubMed ID: 11853992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a better identification and treatment of schizophrenia prodrome.
    Bota RG; Sagduyu K; Filin EE; Bota DA; Munro S
    Bull Menninger Clin; 2008; 72(3):210-27. PubMed ID: 18990056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Attenuated psychotic symptoms syndrome" as a risk syndrome of psychosis, diagnosis in DSM-V: The debate.
    Shrivastava A; McGorry PD; Tsuang M; Woods SW; Cornblatt BA; Corcoran C; Carpenter W
    Indian J Psychiatry; 2011 Jan; 53(1):57-65. PubMed ID: 21431011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and early intervention in schizophrenia: facts and visions.
    Häfner H
    Seishin Shinkeigaku Zasshi; 2002; 104(11):1033-54. PubMed ID: 12642908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Integrative studies for early psychosis: toward realizing youth mental health].
    Kasai K
    Seishin Shinkeigaku Zasshi; 2011; 113(7):679-87. PubMed ID: 21882542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals.
    Asevedo E; Cunha GR; Zugman A; Mansur RB; Brietzke E
    Rev Neurosci; 2012; 23(4):353-62. PubMed ID: 22944654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First-episode psychosis, cognitive difficulties and remediation].
    Vidailhet P
    Encephale; 2013 Sep; 39 Suppl 2():S83-92. PubMed ID: 24084427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Young rural people at risk for schizophrenia: time for mental health services to translate research evidence into best practice of care.
    Stain HJ; Clark S; O'Donnell M; Schall U
    Aust N Z J Psychiatry; 2010 Oct; 44(10):872-82. PubMed ID: 20932200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.